Stockscreener 앱 받기
42.24
1.68%
-0.72
시간 외 거래:
42.24
전일 마감가:
$42.96
열려 있는:
$43.46
하루 거래량:
673.35K
Relative Volume:
0.49
시가총액:
$3.00B
수익:
-
순이익/손실:
$-218.28M
주가수익비율:
-11.80
EPS:
-3.5803
순현금흐름:
$-186.55M
1주 성능:
+3.15%
1개월 성능:
-9.08%
6개월 성능:
+99.81%
1년 성능:
+22.26%
1일 변동 폭
$41.46
$43.49
1주일 범위
$41.32
$44.96
52주 변동 폭
$18.53
$56.05
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
42.24 | 3.05B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 개시 | BofA Securities | Buy |
| 2025-08-04 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | 재개 | H.C. Wainwright | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2025-01-28 | 개시 | Goldman | Buy |
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera Therapeutics, Inc. $VERA Shares Purchased by Candriam S.C.A. - MarketBeat
Vera Therapeutics, Inc. (VERA): A Bull Case Theory - Insider Monkey
Assessing Vera Therapeutics (VERA) Valuation As Atacicept Nears FDA Decision And Commercial Leadership Shifts - Sahm
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Quarterly Earnings: Can Vera Therapeutics Inc deliver consistent EPS growthJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Two new Vera Therapeutics hires get stock options and 4-year RSUs - Stock Titan
(VERA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Vera’s New Commercial Chief for Atacicept Reshaping the Investment Case for Vera Therapeutics (VERA)? - Sahm
Vera Therapeutics, Inc. (VERA) Stock Analysis: Exploring a 65.98% Potential Upside for a Biotech Innovator - DirectorsTalk Interviews
Is Vera’s New Commercial Chief And Atacicept Launch Push Altering The Investment Case For Vera Therapeutics (VERA)? - Yahoo Finance
Vera Therapeutics Readies Atacicept Launch As New CCO Joins, Valuation Lags - Yahoo Finance
Vera Therapeutics Appoints New Chief Commercial Officer - intellectia.ai
Vera Therapeutics Adds CCO As Atacicept Advances And Valuation Gap Persists - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? - Insider Monkey
Is Vera Therapeutics (VERA) one of the best high short interest stocks with biggest upside potential? - MSN
Y Intercept Hong Kong Ltd Buys New Shares in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics, Inc. $VERA Shares Bought by J. Safra Sarasin Holding AG - MarketBeat
Is Vera Therapeutics (VERA) Attractive After Recent Share Price Pullback And DCF Upside? - simplywall.st
Aug Intraday: Whats next for Digimarc Corporation stockNew Guidance & Technical Pattern Recognition Alerts - baoquankhu1.vn
Vera Therapeutics promotes Matt Skelton to chief commercial officer By Investing.com - Investing.com South Africa
Vera Therapeutics promotes Matt Skelton to chief commercial officer - Investing.com
Vera Therapeutics Appoints Matt Skelton as Chief Commercial Officer Amid Commercial Launch Preparations for Atacicept - Quiver Quantitative
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer - The Manila Times
Shorts Report: Is LMAT subject to activist investor interestWeekly Trade Summary & High Accuracy Investment Signals - baoquankhu1.vn
Vera Therapeutics, Inc. (VERA) Stock Analysis: Unpacking A 59% Upside Potential - DirectorsTalk Interviews
JPMorgan reiterates Overweight rating on Vera Therapeutics stock By Investing.com - Investing.com Canada
Assessing Vera Therapeutics (VERA) Valuation After Phase Three Success And AI Drug Discovery Progress - Sahm
Responsive Playbooks and the VERA Inflection - Stock Traders Daily
What Vera Therapeutics (VERA)'s Phase 3 Kidney Trial Win and AI Push Mean For Shareholders - Sahm
Big Picture: Does Vera Therapeutics Inc align with a passive investing strategy - baoquankhu1.vn
Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns - Yahoo Finance
SG Americas Securities LLC Takes $911,000 Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Buyout Rumor: Is Vera Therapeutics Inc vulnerable to short sellersWeekly Investment Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Insider Buy: Whats the analyst consensus on Vera Therapeutics IncTake Profit & Safe Capital Investment Plans - baoquankhu1.vn
Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock By Investing.com - Investing.com Canada
Published on: 2026-01-16 22:59:19 - baoquankhu1.vn
Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept - Insider Monkey
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? - sharewise.com
Understanding the Setup: (VERA) and Scalable Risk - Stock Traders Daily
Vera Therapeutics, Inc. (VERA) Stock Analysis: A 62% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Vera Therapeutics (NASDAQ:VERA) Shares Down 7.4%Here's Why - MarketBeat
Why Vera Therapeutics stock zoomed higher today - MSN
Assessing Vera Therapeutics (VERA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Short report: Vera Therapeutics bears retreat as stock rallies - MSN
Does FDA Priority Review For Atacicept Reshape The Bull Case For Vera Therapeutics (VERA)? - Yahoo Finance
Will Vera Therapeutics Inc. stock split again soonJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - Улправда
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
베라 테라 주식 (VERA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Turner William D. | Chief Regulatory Officer |
Dec 15 '25 |
Sale |
50.08 |
10,000 |
500,767 |
22,500 |
| ENRIGHT PATRICK G | Director |
Dec 11 '25 |
Buy |
42.50 |
5,882 |
249,985 |
5,882 |
1.24%
0.19%
자본화:
|
볼륨(24시간):